Sandra Vedrick | Director of Investor Relations and Human Resources |
George Tidmarsh | President and Chief Executive Officer |
Dennis Mulroy | Chief Financial Officer |
Jennifer Carver | Chief Operating Officer |
Joon Lee | SunTrust Robinson |
Phil Nadeau | Cowen and Company |
Kyung Yang | Jefferies |
Ed White | H.C. Wainwright |
Tessa Romero | JPMorgan |
Welcome to the La Jolla Pharmaceutical Company Fourth Quarter and Full Year 2018 Financial Results Call. At this time, all participants are in a listen-only mode. Later, we will conduct the question-and-answer session and instructions will follow at that time [Operator Instructions]. On today's call, La Jolla will be making forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including but not limited to, statements related to La Jolla’s expectations regarding net sales and net cash used in operating activities for the full-year 2019, the expectations regarding future clinical and regulatory milestones, such as expected NDA submission and approvals and expected timing for commencement and completion of clinical studies. These statements relate to expectations regarding future events or La Jolla’s future results of operations.